Effect of SGLT2 inhibitors on anemia and their possible clinical implications

Area of Science:

• Cardiovascular medicine
• Nephrology
• Endocrinology

Background:

• Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are established treatments for type 2 diabetes, heart failure, and chronic kidney disease.
• An initial observation of increased hemoglobin/hematocrit with SGLT2i was attributed to hemoconcentration.
• Emerging evidence suggests SGLT2i positively impact erythropoiesis and iron metabolism.

Purpose of the Study:

• To review the mechanisms by which SGLT2i enhance erythropoiesis.
• To explore the link between SGLT2i-induced hemoglobin increase and cardiorenal benefits.
• To elucidate the role of improved iron metabolism in SGLT2i efficacy.

Main Methods:

• Review of existing literature on SGLT2i, erythropoiesis, and cardiorenal outcomes.
• Analysis of mediation studies investigating hemoglobin increase as a factor in SGLT2i benefits.
• Discussion of preclinical and clinical data on SGLT2i effects on erythropoietin and iron pathways.

Main Results:

• SGLT2i increase erythropoietin levels and stimulate erythropoiesis.
• Improved iron metabolism, including increased transferrin and reduced hepcidin, is observed with SGLT2i use.
• Hemoglobin increase is a significant mediator of the cardiorenal protective effects of SGLT2i.

Conclusions:

• SGLT2i enhance erythropoiesis through multiple mechanisms, including increased erythropoietin and improved iron availability.
• The rise in hemoglobin is a key factor contributing to the cardiorenal benefits of SGLT2i.
• Understanding these mechanisms provides further insight into the therapeutic potential of SGLT2i in cardiorenal disease.